BioRestorative Therapies
BRTX
14 hedge funds and large institutions have $1.73M invested in BioRestorative Therapies in 2022 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
27% more funds holding
Funds holding: 11 → 14 (+3)
0% more capital invested
Capital invested by funds: $1.72M → $1.73M (+$3.1K)
1.92% less ownership
Funds ownership: 11.37% → 9.45% (-1.9%)
80% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$99.3K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$47.1K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.01K |
| 4 |
Morgan Stanley
New York
|
+$108 |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$56 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Ayrton Capital
Westport,
Connecticut
|
-$151K |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$103K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$75.1K |
| 4 |
SG
StoneX Group
New York
|
-$64.9K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$43K |
BRTX Hedge Fund Activity: Q1 2022 in Review
14 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in BioRestorative Therapies (BRTX) for Q1 2022, worth a combined $1.73M — up 0.18% from $1.72M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BRTX positions and 3 closed out — a net gain of 3 holders — while 1 added to existing stakes and 5 trimmed.
The largest buyer was Cambridge Investment Research Advisors, opening a new position worth an estimated $99.3K. The largest seller was Ayrton Capital, cutting an estimated $151K.
- 14 institutional investors held BioRestorative Therapies (BRTX) as of Q1 2022, up from 11 in Q4 2021.
- Funds reported $1.73M of BioRestorative Therapies stock for Q1 2022, up 0.18% quarter-over-quarter.
- 6 funds opened new BioRestorative Therapies positions in Q1 2022 and 3 closed out, a net change of +3 holders.
- The largest BioRestorative Therapies buyer in Q1 2022 was Cambridge Investment Research Advisors, an estimated $99.3K added.
- The largest BioRestorative Therapies seller in Q1 2022 was Ayrton Capital, an estimated $151K sold.
Based on aggregated 13F filings for Q1 2022.